Chantal Chenu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chantal Chenu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Cécile Itzstein
INSERM Unit 403, Hôpital E. Herriot, Pavillon F, 69437 LYON Cedex 03, France
2 shared publicationsHervé Cheynel
INSERM Unit 403, Hôpital E. Herriot, Pavillon F, 69437 LYON Cedex 03, France
2 shared publicationsPierre D. Delmas
INSERM Unit 403, Hôpital E. Herriot, Pavillon F, 69437 LYON Cedex 03, France
2 shared publicationsB. Burt-Pichat
INSERM, Unit 403, Hôpital E. Herriot, Pavillon F, Lyon, Cedex, France
1 shared publicationBlandine Merle
INSERM Unit 403, Hôpital E. Herriot, Pavillon F, 69437 LYON Cedex 03, France
1 shared publicationBrigitte Burt‐Pichat
INSERM Unit 403, Hôpital E. Herriot, Pavillon F, 69437 LYON Cedex 03, France
1 shared publication
Latest Publications
- 1 September 2002
- Vol. 2 (5) , 423-31
Glutamatergic regulation of bone resorption.
There has been increasing evidence during the last years that glutamate (Glu), the major neuromediator of the nervous system, contributes to the local regulation of bone cell functions. Several classes of Glu receptors and transporters, as well as molecules involved in glutamate signal transduction in neuronal tissue, were identified in bone. While recent findings suggest that Glu may participate in mechanisms underlying bone formation, several studies indicate that Glu may also control bone resorption. Ionotropic NMDA and metabotropic Glu receptors are expressed by osteoclasts and electrophysiological studies have demonstrated that NMDA receptors (NMDAR) are functional on these cells. In vitro studies have shown that NMDAR are important for osteoclast function since several specific antagonists of NMDAR which block the current induced by Glu in these cells also inhibit bone resorption. Preliminary studies investigating the mechanisms of action of NMDAR antagonists on bone resorption are reviewed in this paper. There is also growing evidence that NMDAR are expressed throughout the osteoclastic differentiation sequence and that antagonists of NMDAR affect osteoclastogenesis. Very few in vivo studies have however investigated the role of Glu in skeletal metabolism and bone resorption and clearly further work is required to demonstrate the relevance of glutamate signaling in the physiology of bone resorption in vivo.
- 1 September 2002
- Vol. 2 (5) , 423-31
Glutamatergic regulation of bone resorption.
There has been increasing evidence during the last years that glutamate (Glu), the major neuromediator of the nervous system, contributes to the local regulation of bone cell functions. Several classes of Glu receptors and transporters, as well as molecules involved in glutamate signal transduction in neuronal tissue, were identified in bone. While recent findings suggest that Glu may participate in mechanisms underlying bone formation, several studies indicate that Glu may also control bone resorption. Ionotropic NMDA and metabotropic Glu receptors are expressed by osteoclasts and electrophysiological studies have demonstrated that NMDA receptors (NMDAR) are functional on these cells. In vitro studies have shown that NMDAR are important for osteoclast function since several specific antagonists of NMDAR which block the current induced by Glu in these cells also inhibit bone resorption. Preliminary studies investigating the mechanisms of action of NMDAR antagonists on bone resorption are reviewed in this paper. There is also growing evidence that NMDAR are expressed throughout the osteoclastic differentiation sequence and that antagonists of NMDAR affect osteoclastogenesis. Very few in vivo studies have however investigated the role of Glu in skeletal metabolism and bone resorption and clearly further work is required to demonstrate the relevance of glutamate signaling in the physiology of bone resorption in vivo.
- 15 July 2002
- Published by Wiley in Microscopy Research and Technique
- Vol. 58 (2) , 70-76
Glutamatergic innervation in bone
Bone is highly innervated, and evidence for a regulation of bone metabolism by nerve fibers has been suggested by many clinical and experimental studies. However, the nature of the neuromediators involved in these processes has not been well documented. Glutamate (Glu), a major neuromediator of the central nervous system (CNS), was recently identified in nerve fibers running in bone marrow in close contact with bone cells, suggesting that Glu may also act as a neuromediator in this tissue. During the last few years, all the machinery required for glutamate signalling in the CNS was demonstrated in bone. Osteoblasts and osteoclasts express ionotropic Glu receptors (iGluR) (NMDA, AMPA, and Kainate) and metabotropic Glu receptors (mGluR) as well as Glu transporters. Electrophysiological studies have demonstrated that NMDA receptors (NMDAR) and mGluR are functional on bone cells. NMDAR are involved in osteoclast formation and bone resorption and preliminary studies suggest that they may also participate in mechanisms underlying osteoblast proliferation or differentiation, providing evidence for a direct action of Glu on bone cells. The bone loss induced in a model of sciatic neurectomy in growing rats is associated with a decrease of glutamatergic innervation, suggesting that Glu released by nerve fibers may contribute to the regulation of bone remodeling. The manipulation of Glu action in bone may, therefore, represent a new therapeutic target for pathologies associated with modifications of bone remodeling. Microsc. Res. Tech. 58:70–76, 2002.
- 15 July 2002
- Published by Wiley in Microscopy Research and Technique
- Vol. 58 (2) , 70-76
Glutamatergic innervation in bone
Bone is highly innervated, and evidence for a regulation of bone metabolism by nerve fibers has been suggested by many clinical and experimental studies. However, the nature of the neuromediators involved in these processes has not been well documented. Glutamate (Glu), a major neuromediator of the central nervous system (CNS), was recently identified in nerve fibers running in bone marrow in close contact with bone cells, suggesting that Glu may also act as a neuromediator in this tissue. During the last few years, all the machinery required for glutamate signalling in the CNS was demonstrated in bone. Osteoblasts and osteoclasts express ionotropic Glu receptors (iGluR) (NMDA, AMPA, and Kainate) and metabotropic Glu receptors (mGluR) as well as Glu transporters. Electrophysiological studies have demonstrated that NMDA receptors (NMDAR) and mGluR are functional on bone cells. NMDAR are involved in osteoclast formation and bone resorption and preliminary studies suggest that they may also participate in mechanisms underlying osteoblast proliferation or differentiation, providing evidence for a direct action of Glu on bone cells. The bone loss induced in a model of sciatic neurectomy in growing rats is associated with a decrease of glutamatergic innervation, suggesting that Glu released by nerve fibers may contribute to the regulation of bone remodeling. The manipulation of Glu action in bone may, therefore, represent a new therapeutic target for pathologies associated with modifications of bone remodeling. Microsc. Res. Tech. 58:70–76, 2002.
- 1 March 2002
- Vol. 2 (3) , 282-4
Glutamatergic regulation of bone remodeling.
L-glutamate (Glu) is the predominant neuromediator in the mammalian central nervous system (CNS). Bone is highly innervated and there is growing evidence of a neural control of bone cell metabolism. The recent discovery of Glu-containing nerve fibers in bone and Glu receptors (GluR) and transporters in bone cells suggest that this neuromediator may also act as a signaling molecule in bone and regulate bone cell function. Our previous studies have demonstrated that ionotropic N-Methyl-D-Aspartate (NMDA) GluR are highly expressed by mammalian osteoclasts. NMDA receptors (NMDAR) are heteromers associating the NR1 subunit and one of the four types of NR2 subunits (NR2A to D). We showed that osteoclasts express NR1, NR2B and NR2D subunits, suggesting a molecular diversity of NMDAR in these cells. Electrophysiological studies have confirmed that NMDAR are functional in mature osteoclasts, and features of Glu-induced current recorded in these cells indicate a major NR2D subunit composition. Using an in vitro assay of bone resorption, we showed that several antagonists of NMDAR binding to different sites of the receptor inhibit bone resorption. In particular, the specific NMDAR channel blocker MK801 had no effect on osteoclast attachment to bone and survival while it rapidly decreased the percentage of osteoclasts with actin ring structures that are associated with actively resorbing osteoclasts. NMDAR may thus be involved in adhesion-induced formation of the sealing zone required for bone resorption. NMDAR are also expressed by osteoclast precursors isolated from mouse bone marrow. We recently confirmed the presence of NR1, NR2B and NR2D in these cells and demonstrated their expression at all differentiation stages from osteoclast precursors to mature resorbing osteoclasts. No regulation of these subunits mRNA expression levels was observed throughout the osteoclastic differentiation sequence. Activation of NMDAR may therefore represent a new mechanism for regulating osteoclast formation and activity. While the origin of Glu in bone is still unknown, the possibility of a glutamatergic neurotransmission in this tissue is suggested by the detection of Glu in nerve fibers in close contact to bone cells. Furthermore, we recently demonstrated that sciatic neurectomy in growing rats induces a bone loss associated with a reduction of nerve profiles immunostained for Glu. These results suggest that Glu may be released from glutamatergic nerve profiles present in bone and therefore contribute to the local regulation of bone cell function.
- 1 March 2002
- Vol. 2 (3) , 282-4
Glutamatergic regulation of bone remodeling.
L-glutamate (Glu) is the predominant neuromediator in the mammalian central nervous system (CNS). Bone is highly innervated and there is growing evidence of a neural control of bone cell metabolism. The recent discovery of Glu-containing nerve fibers in bone and Glu receptors (GluR) and transporters in bone cells suggest that this neuromediator may also act as a signaling molecule in bone and regulate bone cell function. Our previous studies have demonstrated that ionotropic N-Methyl-D-Aspartate (NMDA) GluR are highly expressed by mammalian osteoclasts. NMDA receptors (NMDAR) are heteromers associating the NR1 subunit and one of the four types of NR2 subunits (NR2A to D). We showed that osteoclasts express NR1, NR2B and NR2D subunits, suggesting a molecular diversity of NMDAR in these cells. Electrophysiological studies have confirmed that NMDAR are functional in mature osteoclasts, and features of Glu-induced current recorded in these cells indicate a major NR2D subunit composition. Using an in vitro assay of bone resorption, we showed that several antagonists of NMDAR binding to different sites of the receptor inhibit bone resorption. In particular, the specific NMDAR channel blocker MK801 had no effect on osteoclast attachment to bone and survival while it rapidly decreased the percentage of osteoclasts with actin ring structures that are associated with actively resorbing osteoclasts. NMDAR may thus be involved in adhesion-induced formation of the sealing zone required for bone resorption. NMDAR are also expressed by osteoclast precursors isolated from mouse bone marrow. We recently confirmed the presence of NR1, NR2B and NR2D in these cells and demonstrated their expression at all differentiation stages from osteoclast precursors to mature resorbing osteoclasts. No regulation of these subunits mRNA expression levels was observed throughout the osteoclastic differentiation sequence. Activation of NMDAR may therefore represent a new mechanism for regulating osteoclast formation and activity. While the origin of Glu in bone is still unknown, the possibility of a glutamatergic neurotransmission in this tissue is suggested by the detection of Glu in nerve fibers in close contact to bone cells. Furthermore, we recently demonstrated that sciatic neurectomy in growing rats induces a bone loss associated with a reduction of nerve profiles immunostained for Glu. These results suggest that Glu may be released from glutamatergic nerve profiles present in bone and therefore contribute to the local regulation of bone cell function.
- 17 April 2001
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 82 (1) , 134-144
Molecular identification of NMDA glutamate receptors expressed in bone cells
The N‐methyl‐D‐aspartate (NMDA) subtype of the glutamate receptor has recently been identified in bone, but the molecular composition of this receptor expressed by bone cells is unknown. NMDA receptor (NMDAR) is a hetero‐oligomeric protein composed of two classes of subunits, the essential subunit NR1 and NR2A to D subunits that do not by themselves produce functional channels but potentiate NR1 activity and confer functional variability to the receptor. These subunits coassemble in different combinations to form functionally distinct NMDAR. In this study, we have investigated the molecular composition of NMDAR expressed by osteoblasts and osteoclasts in culture, using RT‐PCR analysis, in situ hybridization and immunocytochemistry. Specific probes were designed for the different subunits of the NMDAR, and we showed by RT‐PCR analysis that mammalian osteoclasts expressed NR2B and NR2D subunits mRNAs but not NR2A and NR2C mRNAs. Rat calvaria and MG63 osteoblastic cells also expressed several NR2 subunits mRNAs, namely NR2A, NR2B, and NR2D. In situ hybridization on isolated rabbit osteoclasts and MG63 cells has confirmed the localization of NR1, NR2B, and NR2D transcripts in osteoclasts and NR1, NR2A, NR2B, and NR2D transcripts in MG63 cells. The expression of NR2D protein by bone cells was shown by immunofluorescence. These results demonstrate for the first time that osteoblasts and osteoclasts express several NR2 subunits, suggesting a molecular diversity of NMDAR channels similar to what was shown for brain. The presence of distinct functional NMDAR on bone cells may be associated with various states of bone cell differentiation and function. J. Cell. Biochem. 82: 134–144, 2001.
- 17 April 2001
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 82 (1) , 134-144
Molecular identification of NMDA glutamate receptors expressed in bone cells
The N‐methyl‐D‐aspartate (NMDA) subtype of the glutamate receptor has recently been identified in bone, but the molecular composition of this receptor expressed by bone cells is unknown. NMDA receptor (NMDAR) is a hetero‐oligomeric protein composed of two classes of subunits, the essential subunit NR1 and NR2A to D subunits that do not by themselves produce functional channels but potentiate NR1 activity and confer functional variability to the receptor. These subunits coassemble in different combinations to form functionally distinct NMDAR. In this study, we have investigated the molecular composition of NMDAR expressed by osteoblasts and osteoclasts in culture, using RT‐PCR analysis, in situ hybridization and immunocytochemistry. Specific probes were designed for the different subunits of the NMDAR, and we showed by RT‐PCR analysis that mammalian osteoclasts expressed NR2B and NR2D subunits mRNAs but not NR2A and NR2C mRNAs. Rat calvaria and MG63 osteoblastic cells also expressed several NR2 subunits mRNAs, namely NR2A, NR2B, and NR2D. In situ hybridization on isolated rabbit osteoclasts and MG63 cells has confirmed the localization of NR1, NR2B, and NR2D transcripts in osteoclasts and NR1, NR2A, NR2B, and NR2D transcripts in MG63 cells. The expression of NR2D protein by bone cells was shown by immunofluorescence. These results demonstrate for the first time that osteoblasts and osteoclasts express several NR2 subunits, suggesting a molecular diversity of NMDAR channels similar to what was shown for brain. The presence of distinct functional NMDAR on bone cells may be associated with various states of bone cell differentiation and function. J. Cell. Biochem. 82: 134–144, 2001.
- Open Access
- 1 July 1999
- Published by Wiley in The Journal of Physiology
- Vol. 518 (1) , 47-53
Active NMDA glutamate receptors are expressed by mammalian osteoclasts
1 The N‐methyl‐D‐aspartate (NMDA) glutamate receptor, widely distributed in the mammalian nervous system, has recently been identified in bone. In this study, we have investigated whether NMDA receptors expressed by osteoclasts have an electrophysiological activity. 2 Using the patch clamp technique two agonists of the NMDA receptor, L‐glutamate (Glu) and NMDA, were shown to activate whole‐cell currents recorded in isolated rabbit osteoclasts. 3 The current‐voltage (I‐V) relationships of the currents induced by Glu (IGlu) and NMDA (INMDA) were studied using Mg2+‐free solutions. The agonist‐induced currents had a linear I‐V relationship with a reversal potential near 0 mV, as expected for a voltage independent and non‐selective cationic current. 4 I Glu and INMDA were sensitive to specific blockers of NMDA subtype glutamate receptors, such as magnesium ions, (5R, 10S)‐(+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo[a, d]cyclohepten ‐5,10‐imine (MK‐801) and 1‐(1,2‐diphenylethyl) piperidine (DEP). The block of IGlu and INMDA by these specific antagonists was voltage dependent, strong for negative potentials (inward current) and absent for positive potentials (outward current). 5 These results demonstrate that NMDA receptors are functional in rabbit osteoclasts, and that their electrophysiological and pharmacological properties in these cells are similar to those documented for neuronal cells. Active NMDA receptors expressed by osteoclasts may represent a new target for regulating bone resorption.
- 1 July 1999
- Published by Wiley in The Journal of Physiology
- Vol. 518 (1) , 47-53
Open AccessActive NMDA glutamate receptors are expressed by mammalian osteoclasts
1 The N‐methyl‐D‐aspartate (NMDA) glutamate receptor, widely distributed in the mammalian nervous system, has recently been identified in bone. In this study, we have investigated whether NMDA receptors expressed by osteoclasts have an electrophysiological activity. 2 Using the patch clamp technique two agonists of the NMDA receptor, L‐glutamate (Glu) and NMDA, were shown to activate whole‐cell currents recorded in isolated rabbit osteoclasts. 3 The current‐voltage (I‐V) relationships of the currents induced by Glu (IGlu) and NMDA (INMDA) were studied using Mg2+‐free solutions. The agonist‐induced currents had a linear I‐V relationship with a reversal potential near 0 mV, as expected for a voltage independent and non‐selective cationic current. 4 I Glu and INMDA were sensitive to specific blockers of NMDA subtype glutamate receptors, such as magnesium ions, (5R, 10S)‐(+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo[a, d]cyclohepten ‐5,10‐imine (MK‐801) and 1‐(1,2‐diphenylethyl) piperidine (DEP). The block of IGlu and INMDA by these specific antagonists was voltage dependent, strong for negative potentials (inward current) and absent for positive potentials (outward current). 5 These results demonstrate that NMDA receptors are functional in rabbit osteoclasts, and that their electrophysiological and pharmacological properties in these cells are similar to those documented for neuronal cells. Active NMDA receptors expressed by osteoclasts may represent a new target for regulating bone resorption.